- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.03. | Advicenne: Strong improvement of 2023 results thanks to sustained commercial activity on Sibnayal | 292 | Business Wire | Sibnayal volume up 84%.
Gross sales exceed €4 million for the first time.
Sharp decrease in net loss to -7.03 M€ vs. -11.47 M€ in 2022.
Year-end cash position at €5.25 million... ► Artikel lesen | |
| 25.03. | Advicenne: FDA Grants Orphan Drug Designation to ADV7103 for the Treatment of Cystinuria. | 320 | Business Wire | After distal Renal Tubular Acidosis (dRTA) in December 2022, ADV7103 is granted "orphan drug" status in the United States in cystinuria. A long-awaited milestone for the Company and its flagship... ► Artikel lesen | |
| 23.01. | Advicenne Reports 2023 Gross Sales1 up 20% to €4.43 Million | 260 | Business Wire | PARIS--(BUSINESS WIRE)--Regulatory News:
Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative... ► Artikel lesen | |
| 28.12.23 | Advicenne Announces Its 2024 Financial Calendar | 382 | Business Wire | Regulatory News:
Advicenne(Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 18.10.23 | Avanzanite Bioscience B.V.: Avanzanite Bioscience Expands Partnership With Advicenne in Additional European Countries | 420 | Business Wire | Expanded collaboration now includes Ireland, Cyprus and Malta in addition to existing markets of Germany, Austria, Switzerland, Greece and Liechtenstein.
Advicenne expanded partnership validates... ► Artikel lesen | |
| 02.10.23 | Advicenne announces the results of its capital increase with preferential subscription rights | 408 | Business Wire | Subscription of €5.7 million representing 95% of the initial amount Cemag Invest and Bpifrance now own respectively 18.0% and 21.6% of equity and 17.6% and 23.6% of voting rights
Regulatory... ► Artikel lesen | |
| 25.09.23 | Advicenne Announces Its Participation in Several Scientific Conferences and the Presentation of Updated Clinical Results About ADV7103 | 420 | Business Wire | Regulatory News:
Advicenne(Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 13.09.23 | XFRA CAPITAL ADJUSTMENT INFORMATION - 13.09.2023 | 1.489 | Xetra Newsboard | Das Instrument GEY CH0114405324 GARMIN LTD NAM.SF 0,10 EQUITY wird cum Kapitalmassnahme gehandelt am 13.09.2023 und ex Kapitalmassnahme am 14.09.2023 The instrument GEY CH0114405324 GARMIN LTD NAM.SF... ► Artikel lesen | |
| 11.09.23 | Advicenne Launches a Capital Increase With Preferential Subscription Rights ("PSR") to Accelerate Growth in Europe and Optimize Clinical Development of ADV7103 | 365 | Business Wire | Capital increase with pre-emptive subscription rights ("PSR") for an initial amount of €6.0 million, which may be increased to €6.9 million if the Extension Clause is fully exercised. Subscription... ► Artikel lesen | |
| 11.09.23 | Advicenne Reports its First Half Financial Results as of June 30, 2023 and Updates on Its Activities | 297 | Business Wire | 51% increase in Sibnayal® gross sales to €0.96 million Significant reduction in operating losses to €2.9 million (vs. €4.4 million in H1 2022) €0.9 million improvement in cash flow... ► Artikel lesen | |
| 12.07.23 | Advicenne Announces 51% Growth in Sibnayal Gross Sales in H1 2023 to almost €1.0 Million | 393 | Business Wire | Advicenne first-half 2023 gross sales1 up 23% to 2.2 million euros Sales of Sibnayal® (potassium citrate/potassium hydrogen carbonate) up 128% in volume terms Sibnayal® becomes the... ► Artikel lesen | |
| 14.06.23 | Advicenne Announces Long-Term Results of the European Clinical Development Program for ADV7103 | 563 | Business Wire | Regulatory News:
Advicenne(Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 09.06.23 | Advicenne announces the approval of all resolutions supported by the Board of Directors at its Combined General Meeting | 326 | Business Wire | Regulatory News:
The Combined General Meeting of shareholders of Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization... ► Artikel lesen | |
| 19.05.23 | Advicenne annual combined general meeting of June 8, 2023 | 451 | Business Wire | Availability of preparatory documents
Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746)(Paris:ALDVI), a specialty pharmaceutical company dedicated to the development and... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 25,840 | -0,04 % | Novo Nordisk, Pfizer und Co.: Bei welcher Big Biotech-Aktie sollten Anleger jetzt zuschlagen? | Neue Quartalszahlen haben gerade einige der wichtigsten Biotech-Aktien in Bewegung gebracht. Wir geben einen Überblick, wo sich für Anleger jetzt ein Investment lohnen könnte. Hinter der Biotech-Branche... ► Artikel lesen | |
| ABBVIE | 152,30 | +0,08 % | AbbVie investiert rund 150 Millionen Euro in die Zukunft der Spitzenforschung am Standort Ludwigshafen | Ludwigshafen (ots) - - Modernste Rahmenbedingungen für Forscher*innen im Kampf gegen u.a. Alzheimer und Krebs - Investition unterstreicht Bedeutung des rheinland-pfälzischen Standorts für AbbVie im... ► Artikel lesen | |
| HAEMATO | 17,400 | -3,33 % | XFRA DELETION OF INSTRUMENTS FROM XETRA - 17.04.2024 | The following instruments on XETRA do have their last trading day on 17.04.2024Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 17.04.2024ISIN NameDE000LB32W75 LBBW FZA 22/24DE000DW6C4A6... ► Artikel lesen | |
| HALEON | 3,848 | -0,62 % | Aktien Europa: Londoner Handel vor US-Zinsentscheid solide - Vielerorts Feiertag | PARIS/LONDON (dpa-AFX) - Unter den wichtigsten europäischen Börsen wird am Mittwoch feiertagsbedingt nur in London gehandelt. Vor dem US-Zinsentscheid legte der Leitindex FTSE 100 gegen Mittag leicht... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 4,285 | -2,61 % | Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update | SEATTLE and VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 67,50 | +1,50 % | Ligand Pharmaceuticals Incorporated: Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference | Captisol-enabled Topiramate Injection shown to be a substitute for an oral dose on a one-to-one basis
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partners at the... ► Artikel lesen | |
| DR REDDYS | 69,00 | +0,73 % | DR REDDYS LABORATORIES LTD - 6-K, Report of foreign issuer | ||
| ROYALTY PHARMA | 26,140 | -0,95 % | Dividendenbekanntmachungen (15.02.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 3M COMPANY US88579Y1010 1,51 USD 1,4074 EUR A10 NETWORKS INC US0021211018 0,06 USD 0,0559 EUR ADVANCED ENERGY INDUSTRIES INC US0079731008 0... ► Artikel lesen | |
| TG THERAPEUTICS | 15,236 | +1,21 % | Pre-market Movers: IM Cannabis, CVRx, TG Therapeutics, Root, Inc., Plutonian Acquisition | WOONSOCKET (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 09.00 A.M. ET).In the Green IM Cannabis Corp. (IMCC) is up over 36% at $0.86.
TG... ► Artikel lesen | |
| EISAI | 39,550 | 0,00 % | BioArctic and Eisai sign research evaluation agreement regarding BAN2802 | STOCKHOLM, April 20, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic AB and Eisai Co., Ltd., have entered into a research evaluation agreement... ► Artikel lesen | |
| INTRA-CELLULAR THERAPIES | 64,00 | 0,00 % | Intra-Cellular Therapies Inc.: Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast | ||
| BETTERLIFE PHARMA | 0,074 | +6,52 % | Betterlife Pharma Inc (2): Betterlife Pharma arranges $500,000 private placement | ||
| ENTOURAGE HEALTH | 0,012 | 0,00 % | Entourage Health Corp.: Entourage Health Reports Fiscal Year 2023 Financial Results and Posts $54 Million in Total Revenues | Gross profit before fair value changes reached $2.4 million, reflecting a 126% year-over-year increase.Company demonstrates financial gains with a 23% reduction in the cost of goods sold.SG&A declined... ► Artikel lesen | |
| IGC PHARMA | 0,498 | +3,75 % | XFRA IGS1: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| PURE EXTRACTS TECHNOLOGIES | 0,004 | 0,00 % | Pure Extracts Technologies Corp: Pure Extracts Technologies halted at the open |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
